Keep Current with the Latest in Cell Biology Research

Bellicum Receives FDA IND Clearance to Initiate a Phase I/II Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors

Bellicum Pharmaceuticals, Inc. announced clearance by the FDA of its investigational new drug application for BPX-603. BPX-603 is a GoCAR-T® product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2).
[Bellicum Pharmaceuticals, Inc.]
Bookmark

No account yet? Register

0
Share

Immune Status Could Determine Efficacy of COVID-19 Therapies

Emerging evidence suggests that SARS-CoV-2 can drive a diverse array of immune processes, raising the risk that immunosuppressant agents that are in clinical trials might be effective for some patients but detrimental for others.
[Nature Reviews Drug Discovery]
Press Release
Bookmark

No account yet? Register

0
Share

How Deadly Is the Coronavirus? Scientists Are Close to an Answer

Researchers use a metric called infection fatality rate (IFR) to calculate how deadly a new disease is. It is the proportion of infected people who will die as a result, including those who don’t get tested or show symptoms.
[Nature News]
Press Release
Bookmark

No account yet? Register

0
Share

‘We’ve Got to Be Able to Move More Quickly.’ The Pandemic Reality of COVID-19 Clinical Trials

With speed borne of desperation comes risk and confusion—of trials too small to yield answers, of treatments overhyped, and of uncertainty about how to design the best studies possible. Science spoke with three clinical trial experts about this unprecedented period for modern medical research.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

0
Share

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive therapeutic strategy for cytokine release syndrome, which is a common cause of adverse clinical outcomes in COVID-19.
[Trends in Pharmacological Sciences]
Luo, W., Li, Y.-X., Jiang, L.-J., Chen, Q., Wang, T., & Ye, D.-W. (2020). Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends in Pharmacological Sciences, 0(0). https://doi.org/10.1016/j.tips.2020.06.007 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Variations in Killer-Cell Immunoglobulin-Like Receptor and Human Leukocyte Antigen Genes and Immunity to Malaria

Understanding the role of killer-cell immunoglobulin-like receptors and human leukocyte antigens in immunity to malaria can help to better characterize antimalarial immune responses. The authors summarize the different KIRs and HLAs associated with immunity to malaria thus far.
[Cellular & Molecular Immunology]
Full Article
Bookmark

No account yet? Register

0
Share

Systemically Comparing Host Immunity between Survived and Deceased COVID-19 Patients

Scientists summarized the characteristics of cellular immune responses in a total of 157 COVID-19 patients enrolled in Tongji Hospital between February and March 2020 and compare the properties between 95 survived and 62 deceased patients with different onset time.
[Cellular & Molecular Immunology]
Full Article
Bookmark

No account yet? Register

0
Share

Optimization of Primer Sets and Detection Protocols for SARS-CoV-2 of Coronavirus Disease 2019 (COVID-19) Using PCR and Real-Time PCR

Scientists provide three-step guidelines for the design and optimization of specific primer sets. The three steps include the selection of primer sets for target genes in the genome of SARS-CoV-2, the in silico validation of primer and amplicon sequences, and the optimization of PCR conditions for specific hybridization between the primers and target genes, and the elimination of spurious primer dimers.
[Experimental and Molecular Medicine]
Optimization of primer sets and detection protocols for SARS-CoV-2 of coronavirus disease 2019 (COVID-19) using PCR and real-time PCR | Experimental & Molecular Medicine. (n.d.). Retrieved June 17, 2020, from https://www.nature.com/articles/s12276-020-0452-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Potential Antiviral Options against SARS-CoV-2 Infection

Investigators developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. They identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. They also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine.
[Viruses]
Full Article
Bookmark

No account yet? Register

0
Share

CBASS Immunity Uses CARF-Related Effectors to Sense 3′–5′- and 2′–5′-Linked Cyclic Oligonucleotide Signals and Protect Bacteria from Phage Infection

Investigators discovered Enterobacter cloacae CD-NTase-associated protein 4 (Cap4) as a founding member of a diverse family of >2,000 bacterial receptors that responded to CD-NTase signals. Structures of Cap4 revealed a promiscuous DNA endonuclease domain activated through ligand-induced oligomerization.
[Cell]
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis

Investigators report that periodontal inflammation exacerbates gut inflammation in vivo. Periodontitis led to expansion of oral pathobionts, including Klebsiella and Enterobacter species, in the oral cavity.
[Cell]
The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis: Cell. (n.d.). Retrieved June 17, 2020, from https://www.cell.com/cell/fulltext/S0092-8674(20)30681-4 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share
Share